The Molecular Neurobiology group focuses on improving the understanding of complex rare monogenic neurodevelopmental disorders and developing novel therapeutic options for children who suffer from these disorders. 

Neurodevelopmental disorders are the most common chronic medical conditions encountered in paediatric primary care and encompass highly prevalent conditions such as epilepsy and autism (autism spectrum disorder). Children born with neurodevelopmental disorders can experience difficulties with language and speech, motor skills, behaviour, memory, learning, and other prominent neurological symptoms such as seizures. The primary emphasis of the group centres on pioneering advancements in therapeutic interventions, specifically focusing on innovative treatments like gene therapies and novel drug therapies.

The Molecular Neurobiology Group is led by A/Professor Wendy Gold.